Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

Cisplatin 9Specimen Handling 7Magnetic Resonance Spectroscopy 7Radiotherapy 5Platinum 51,2-diaminocyclohexaneplatinum II citrate 5Biopsy 4Radiotherapy, Intensity-Modulated 3Radiation 3Nivolumab 3Carboplatin 3Immunoglobulin G 2Fluorodeoxyglucose F18 2Disulfides 2Cetuximab 2(225)Ac-DOTA-c(RGDyK) 2pembrolizumab 1niraparib 1ipatasertib 1durvalumab 1dostarlimab 1cemiplimab 1cabozantinib 1atezolizumab 1Watchful Waiting 1Tomography, X-Ray Computed 1Taxes 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Radiotherapy, Image-Guided 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oropharyngeal Neoplasms × ALX148 × 30 days × Clear all
NCT05787639 2026-05-19

Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)

University of California, San Diego

Phase 2 Active not recruiting
29 enrolled
Head & Neck

Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡